Certara Announces Appointment of President of its Software Division

PRINCETON, N.J.—September 17, 2020. Certara, the global leader in biosimulation, today announced the appointment of Leif E. Pedersen as president of its software division, reporting to Chief Executive Officer William F. Feehery, PhD. Mr. Pedersen is a seasoned software industry executive with more than 25 years of experience across a range of software categories. He … Continued

Application of PK/PD Modeling and Simulation in Drug Discovery and Development in China

By Yuancheng Chen, Research Associate of Phase 1 Unit, Huashan Hospital, Fudan University, and visiting scholar of Uppsala University Certara recently held its first virtual Phoenix User Group meeting in China. Over this three-day meeting, attendees learned from Certara’s experts on specific Phoenix workflow examples, updates to the Phoenix product roadmap, an overview the latest … Continued

Accomplish More with Phoenix

Phoenix 8.1, the newest version of Certara’s innovative PK/PD modeling and simulation software used globally by researchers and drug developers in pharma, academia, and regulatory agencies, will be available on June 15, 2018. Major enhancements were introduced in the Phoenix workbench last year. And as an ongoing commitment to support compliance and efficiency, many features … Continued

Modeling PK/PD Systems with Distributed Delays

Many biological systems exhibit time delays. For instance, there is a delay between the time that a virus infects a cell and the onset of viral production. Mathematical models that incorporate these temporal delays are often used to characterize the pharmacokinetics/pharmacodynamics (PK/PD) of drugs. In this blog post, I’ll discuss some examples of biological systems … Continued

Modeling Delayed Outcomes in PK/PD Studies Using DDEs

Delays are ubiquitous in pharmacokinetics (PK) and pharmacodynamics (PD) studies. Transit compartment models, described by systems of ordinary differential equations, have been widely used to describe delayed outcomes in PK and PD studies. The obvious disadvantage for this type of model is it requires manually finding proper values for the number of compartments. In addition, … Continued

Accessing Grid Computing from Your Desktop for NLME

One of the most challenging aspects of population pharmacokinetic/pharmacodynamic (PK/PD) modeling is the lack of computing power required to solve complex models in a reasonable time frame to support rapid drug development decisions. The explosion of cloud computing resources has provided access to significant computing power to solve these complex models. However, accessing these cloud … Continued

1 of 4
Back to top
Powered by Translations.com GlobalLink OneLink Software